All lobbying filings

Ferox Strategies

Ferox Strategies filed a Q4 report for Rare Disease Company Coalition on January 20, 2026, reporting $50,000 in lobbying income.

Lobbying for Rare Disease Company Coalition · Healthcare

As filed: FEROX STRATEGIES for RARE DISEASE COMPANY COALITION.

All filings by Ferox Strategies · Everything Rare Disease Company Coalition has reported

Filing · LD-2 quarterly report Q4 report

Reporting period

4th Quarter 2025

Oct 1 - Dec 31 · Posted Jan 20, 2026

Income

$50,000

What the client paid this registrant for the period.

Client based in

District of Columbia

Official filing document

Government bodies contacted 5

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 3

Taxation/Internal Revenue Code

General issues related to rare disease treatment development.

Health Issues

General issues related to rare disease treatment.

Trade (domestic/foreign)

General issues related to tariffs.

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.